Jose Angel H. R.
- Country
- Spain
- Department
- Hematology
Research Overview
- Efficacy of Ziftomenib Combined with Standard of Care Therapy in Patients with Untreated NPM1-Mutated or KMT2A-Rearranged Acute Myeloid Leukemia
- Phase II Study of Acalabrutinib and Venetoclax in Patients with Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following First-Line BTKi and BCL2 Inhibitor Therapy
- Phase 3 Randomized Double‑Blind Trial of Orelabrutinib Combined with Rituximab and Bendamustine versus Rituximab‑Bendamustine in Treatment‑Naïve Mantle Cell Lymphoma
Data & Insights
Has run more than one trial at 315 of 567 partner sites.
Specializations
Hematologic Malignancies
The investigator specializes in treating various forms of blood cancers, with particular focus on chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Their research extends to novel therapeutic approaches for mantle cell lymphoma and diffuse large B-cell lymphoma.
- Multiple Myeloma Treatment
- Follicular Lymphoma Management
- Acute Myeloid Leukemia Studies
Novel Therapeutics
The investigator explores innovative treatment approaches using targeted therapies including BTK inhibitors and combinations with monoclonal antibodies. Their work includes evaluation of new drug combinations and fixed-duration treatments.
- Targeted Molecular Therapies
- Immunotherapy Applications
- Combination Treatment Strategies
Additional Research Areas
The investigator's expertise extends to treating hypereosinophilic syndrome and managing anticoagulation complications. They also conduct research in COVID-19 prophylaxis and treatment of warm autoimmune hemolytic anemia.
- Blood Disorder Management
- Thrombosis Prevention
- Infectious Disease Research
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.